Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Cybin Inc (CYBN)

Cybin Inc (CYBN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cybin Stock Hits 6-Month High On MDD Treatment's 'Breakthrough’ Efficacy: Retail Turns Extremely Bullish Stocktwits - Mon Nov 18, 10:08AM CST

Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.

PSIL : 11.96 (-0.38%)
CYBN : 10.63 (-4.75%)
Vaccine Stocks Slide, Psychedelic Stocks Surge After RFK Jr. HHS Nomination wealthyventurecapitalist.com - Sat Nov 16, 2:24AM CST

Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...

CMPS : 4.53 (-2.79%)
PSIL : 11.96 (-0.38%)
ATAI : 1.5200 (-4.40%)
AZN : 63.81 (+0.97%)
BVNRY : 9.0400 (+0.17%)
NVAX : 8.06 (+0.37%)
MRNA : 36.74 (-0.54%)
CYBN : 10.63 (-4.75%)
GSK : 33.32 (-0.09%)
PFE : 24.89 (-0.20%)
BNTX : 103.27 (+1.11%)
SNY : 47.85 (+0.15%)
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update Newsfile - Mon Jul 8, 7:50AM CDT

Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update...

CYBN : 10.63 (-4.75%)
CYBN.NE : 15.2000 (-2.38%)
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition FinancialNewsMedia - Wed Jan 24, 8:00AM CST

EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END

CYBN.NE : 15.2000 (-2.38%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 10.63 (-4.75%)
ATAI : 1.5200 (-4.40%)
MNMD : 7.02 (-6.65%)
SEEL : 0.3900 (-27.79%)
CMPS : 4.53 (-2.79%)
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023 Newsfile - Wed Nov 1, 2023

- Interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point Montgomery-Asberg Depression...

CYBN : 10.63 (-4.75%)
CYBN.NE : 15.2000 (-2.38%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise PR Newswire - Wed Sep 20, 2023

/PRNewswire/ -- The demand for abuse deterrent formulation technology is projected to grow due to growing misuse of drugs among the people. Growing demand for...

NTRBW : 1.8000 (+16.13%)
CYBN : 10.63 (-4.75%)
NTRB : 4.83 (-3.01%)
CMND : 1.3300 (-2.21%)
MNMD : 7.02 (-6.65%)
LLY : 740.39 (-1.73%)
Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the Rise FinancialNewsMedia - Wed Sep 20, 2023

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:CMND),(NASDAQ:MNMD),(NYSE:CYBN),(NYSE:LLY) EQNX::TICKER_END

NTRB : 4.83 (-3.01%)
NTRBW : 1.8000 (+16.13%)
CMND : 1.3300 (-2.21%)
MNMD : 7.02 (-6.65%)
CYBN : 10.63 (-4.75%)
LLY : 740.39 (-1.73%)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 FinancialNewsMedia - Wed Jul 26, 2023

EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END

CYBN.NE : 15.2000 (-2.38%)
MMED.NE : 14.9000 (+9.48%)
CYBN : 10.63 (-4.75%)
CMPS : 4.53 (-2.79%)
SEEL : 0.3900 (-27.79%)
MNMD : 7.02 (-6.65%)
NUMIF : 0.0282 (-3.75%)
NUMI.TO : 0.0400 (unch)
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 PR Newswire - Wed Jul 26, 2023

/PRNewswire/ -- Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise...

NUMI.TO : 0.0400 (unch)
CYBN : 10.63 (-4.75%)
CMPS : 4.53 (-2.79%)
MNMD : 7.02 (-6.65%)
SEEL : 0.3900 (-27.79%)
NUMIF : 0.0282 (-3.75%)
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder Newswire.ca - Mon Jul 24, 2023

/CNW/ - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ("Cybin"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by...

CYBN : 10.63 (-4.75%)

Barchart Exclusives

Ambarella Earnings Preview: What to Expect from the Semiconductor Stock in Q3 Barchart - 20 minutes ago
Down almost 80% from all-time highs, Ambarella is a tech stock that trades at a discount to consensus price target estimates. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot